# Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer

> **NCT06247956** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 153 (actual)

## Conditions studied

- Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
- **DRUG:** Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection

## Key facts

- **NCT ID:** NCT06247956
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-11
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06247956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06247956, "Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06247956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*